TrialEye (London, England)2017

Aflibercept as a Second Line Therapy for Neovascular Age Related Macular Degeneration in Israel (ASLI) study.

L Tiosano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.